Myomo Stock Surges After Medicare Certification

Medical robotics company Myomo Inc (NYSE American: MYO) has announced that the Centers for Medicare & Medicaid Services has authorised the company to be a Medicare provider.

The news has seen the company’s share price surge as Myomo are now included in the Medicare Supplier directory, enabling them to bill Medicare directly when it delivers MyoPro powered orthosis in 39 states.

The company is also working on completing the requirements needed in the remaining states.

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

“This certification is very important to Myomo. Not only does it allow us to bill Medicare directly in the future, it also opens the door to applying for in-network contracted coverage from many private commercial insurance companies as well as state Medicaid plans,” said Micah Mitchell, Myomo’s Chief Commercial Officer.

Myomo was previously being reimbursed for MyoPro orthosis on a case-by-case basis by a variety of plans.

Myomo shares…

Myomo’s share price exploded higher after the news and is currently trading at $4.95 per share, up 30% shortly after the US opening bell.

PEOPLE WHO READ THIS ALSO VIEWED: